Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry.

BACKGROUND Profiling approaches in proteomics, such as surface-enhanced laser desorption/ionization (SELDI) mass spectrometry, are used in disease marker discovery. The aim of this study was to investigate the potential influence of selected preanalytical factors on the results obtained. METHODS Plasma samples anticoagulated with EDTA, citrate, or heparin, and serum samples from healthy volunteers were profiled by SELDI on CM10, immobilized metal affinity capture (IMAC) array with copper, and H50 chip surfaces. Using linear mixed-effects models, we examined the influence of elapsed time between venipuncture and sample separation (immediate to 24 h) and the type of serum tube used (Greiner Vacuette activator, gel serum separator, or plain tubes). We analyzed purified platelets, as well as platelet-poor and platelet-rich plasma samples treated with calcium and/or thrombin to determine the platelet contribution, directly or via the clotting process, to the profiles generated. We then used cluster analysis to identify samples with similar peak profiles. RESULTS Different plasma types and sera could be distinguished on the basis of cluster analyses of their spectral profiles. Elapsed time between venipuncture and separation of plasma and serum from blood samples altered the profiles obtained, particularly for serum samples and particularly on IMAC chips. The type of serum collection tube also affected the profiles because of differences in clotting time. In vitro manipulation of platelets revealed that specific peaks in IMAC profiles of serum appeared to be derived directly from platelets. Several other peaks, including some of those exhibiting time-dependent changes, arose during the clotting process. CONCLUSION Preanalytical variables, such as sample handling, can markedly influence results.

[1]  K. Coombes.  Analysis of mass spectrometry profiles of the serum proteome. , 2005, Clinical chemistry.

[2]  F. Marshall.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. , 2005, The Journal of urology.

[3]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[4]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[5]  P. Scheltens,et al.  Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. , 2005, Clinical chemistry.

[6]  G. Hortin.  Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? , 2005, Clinical chemistry.

[7]  G. Hortin,et al.  Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. , 2004, Clinical chemistry.

[8]  K. Baggerly,et al.  Diagnostic protein discovery using proteolytic peptide targeting and identification. , 2004, Rapid communications in mass spectrometry : RCM.

[9]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[10]  P. Walsh.  Platelet coagulation-protein interactions. , 2004, Seminars in thrombosis and hemostasis.

[11]  J. Paulauskis,et al.  Influence of matrix application timing on spectral reproducibility and quality in SELDI-TOF-MS. , 2004, BioTechniques.

[12]  T. Veenstra,et al.  Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool. , 2004 .

[13]  E. Petricoin,et al.  High-resolution serum proteomic features for ovarian cancer detection. , 2004, Endocrine-related cancer.

[14]  E. Petricoin,et al.  An investigation into the human serum “interactome” , 2004, Electrophoresis.

[15]  Timothy Planche,et al.  A novel and accurate diagnostic test for human African trypanosomiasis , 2004, The Lancet.

[16]  Fumio Nomura,et al.  Identification of novel and downregulated biomarkers for alcoholism by surface enhanced laser desorption/ionization‐mass spectrometry , 2004, Proteomics.

[17]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[18]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[19]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[20]  P. Lewczuk,et al.  Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease , 2004, Biological Psychiatry.

[21]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[22]  P. Nickerson,et al.  Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. , 2004, Kidney international.

[23]  W. Guder.  Samples:From the Patient to the Laboratory: The impact of preanalytical variables on the quality of laboratory results , 2003 .

[24]  P. Selby,et al.  Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. , 2003, Cancer research.

[25]  T. Veenstra,et al.  Characterization of the Low Molecular Weight Human Serum Proteome*S , 2003, Molecular & Cellular Proteomics.

[26]  Jeffrey S. Morris,et al.  Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. , 2003, Clinical chemistry.

[27]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[28]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[29]  Weimin Zhu,et al.  Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. , 2003, Journal of proteome research.

[30]  Xudong Huang,et al.  Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease , 2003, The Lancet.

[31]  H C Cordingley,et al.  Multifactorial screening design and analysis of SELDI-TOF ProteinChip array optimization experiments. , 2003, BioTechniques.

[32]  Walter A. Korfmacher,et al.  Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery. , 2003, Rapid communications in mass spectrometry : RCM.

[33]  K. Sekiguchi,et al.  Laminin gamma2-chain fragment in the circulation: a prognostic indicator of epithelial tumor invasion. , 2003, Cancer research.

[34]  E. Dalmasso,et al.  Contribution of Human α-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral Factor , 2002, Science.

[35]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[36]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[37]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[38]  R. Linhardt,et al.  Heparin-protein interactions. , 2002, Angewandte Chemie.

[39]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[40]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[41]  S. Weinberger,et al.  Recent advancements in surface‐enhanced laser desorption/ionization‐time of flight‐mass spectrometry , 2000, Electrophoresis.

[42]  T. Hugli,et al.  Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. , 1999, Clinical chemistry.

[43]  M. Schrader,et al.  Composition of the peptide fraction in human blood plasma: database of circulating human peptides. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[44]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[45]  G. Levin,et al.  Stability of Parathyroid Hormone-Related Protein and Parathyroid Hormone at Room Temperature , 1994, Annals of clinical biochemistry.

[46]  E. Adeyemi,et al.  Augmented release of human leucocyte lactoferrin (and elastase) during coagulation. , 1988, Journal of clinical & laboratory immunology.

[47]  J. H. Ward.  Hierarchical Grouping to Optimize an Objective Function , 1963 .